Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is in a strong position for future growth due to its pipeline of selective oral immunology therapies, targeting chronic inflammatory and autoimmune diseases such as ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. With potential disease modification in RMS, as well as neuroprotection and enhanced neuronal survival, Immunic's vidofludimus calcium has the potential to address key gaps in current treatment approaches. Their recent financing deal of $200M in upfront gross proceeds also provides a strong financial foundation and supports their plans for NDA submission and potential approval in the coming years.

Bears say

Immunic is a clinical-stage biopharmaceutical company with a focus on developing oral immunology therapies for chronic inflammatory and autoimmune diseases. Its current pipeline includes three small molecule products targeting various diseases, with Phase 3 data expected by the end of 2026. However, with previous trials in progressive multiple sclerosis showing only modest improvement, and a lack of differentiation in the market for relapsing multiple sclerosis, combined with the potential risks of clinical and commercial development, there may be limited opportunities for Immunic to achieve success and long-term growth. As of now, it may be prudent for investors to be cautious about investing in this stock.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.